From The Editor

1. Multispecific Manufacturability Starts With Molecular Design 7/21/2026

   AP Biosciences’ VP of antibody discovery, Jhong-Jhe You, Ph.D., explains the key design elements of multispecific antibodies and how they affect product developability.

2. On The Ground At BIO 2026: Johanna Kaufmann, Ph.D., On The Oncology Modality Puzzle 7/10/2026

   At the 2026 BIO International Convention, Bioprocess Online caught up with Johanna Kaufmann, Ph.D., CSO at Deck Bio, a company developing multi-targeted T-cell engagers for solid tumors.

3. BIO 2026: Modernizing The FDA And Bolstering The Workforce 7/10/2026

   Bioprocess Online's chief editor, Tyler Menichiello, shares his key takeaways from the 2026 BIO International Convention in San Diego.

4. BIO 2026: Crowley On Competing With China And Modernizing The FDA 7/8/2026

   Exclusive coverage from John Crowley's press conference at the 2026 BIO International Convention in San Diego.

5. Essential CMC Elements For A Therapeutic Secretome 6/30/2026

   Noveome Biotherapeutics's Larry Brown, Sc.D., explains the regulatory and CMC challenges behind the company's novel secretome therapy, ST266.

6. Midyear Pulse Check: What's Shaping Biopharma In 2026? 6/16/2026

   This article summarizes the major developments and industry pressures highlighted by Life Science Connect editors in the "Better Biopharma" midyear editorial roundtable.

7. Reflecting On Continued Turbulence At The FDA 5/26/2026

   Bioprocess Online's Editorial Advisory Board responds to former FDA commissioner Marty Makary’s resignation amid a prolonged period of instability at the agency.

8. Insufficient Vendor Data Is Hamstringing Single-Use Adoption 5/20/2026

   Audience polls and expert insights reveal insufficient vendor data as the main bottleneck stalling advanced single-use technology adoption. Explore that and other key takeaways in this recap of the Bioprocess Online Live event on "Closing The Adoption Gap For Advanced Single-Use Materials."

9. Can A Biotech Create A CDMO Market? 5/11/2026

   Can a biotech create a CDMO market? GeoVax, an infectious disease/oncology biotech, may have just done so. David Dodd, CEO, believes we should all concentrate more on whether the outsourcing model can align with evolving technology platforms. Both sponsors and CDMOs may need to change things up.

10. On The Ground At NextGen Biomed 2026 4/29/2026

    Bioprocess Online caught up with Tiffany D. Rau, Ph.D., CMC consultant and adjunct professor of biochemistry and cell biology at the University College Cork in Ireland, at Oxford Global's 2026 NextGen Biomed conference.